Order expected to affect specific medications covered under Medicare that are administered in a health care setting.

SGLT2 inhibitors may enable continuation of RAAS inhibitors for hypertension treatment, which is linked with better kidney and cardiovascular outcomes.

Geographic disparities seen, with greater percentage of cardiovascular deaths attributable to di-2-ethylhexylphthalate exposure for South Asia, Middle East.

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.

(HealthDay News) — For female patients with multiple sclerosis (MS), transcutaneous posterior tibial nerve stimulation (TPTNS) and repetitive transcranial magnetic stimulation (rTMS) are comparable ...

(HealthDay News) — The number of kidney transplants performed annually in the United States has increased steadily, but with decreasing allocation efficiency, according to a study published online in ...

Sustainable development efforts such as lowering out-of-pocket health expenses can reduce future prevalence of AMR by 5.1 percent.

Having detectable ctDNA before treatment is associated with worse outcomes among patients with mCRPC, regardless of the treatment they receive.

AstraZeneca has made the decision to end the CAPItello-280 trial evaluating capivasertib in patients with metastatic castration-resistant prostate cancer.

The prophylactic efficacy of TMP-SMX was significantly higher in subgroups with baseline lymphopenia, azotemia, microscopic polyangiitis, or relapsed AAV.

Addition of revascularization to optimized medical therapy not beneficial in patients with carotid stenosis ≥50 percent and low or intermediate predicted stroke risk.